文献速递临床试验与 GCP

健脾活血颗粒治疗非酒精性脂肪性肝病的疗效与安全性:随机双盲安慰剂对照试验的研究方案

Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial.
PubMed 文献 · Trials · 2022-06-02

本研究为随机双盲安慰剂对照试验,计划纳入84例非酒精性脂肪性肝病患者,等比例随机接受健脾活血颗粒或安慰剂治疗24周,干预后12周随访。主要结局为基线至第24周磁共振成像质子密度脂肪分数(MRI-PDFF)的变化,次要结局包括体重、体质指数、腰围、腰臀比、血清肝功能、血脂血糖指标、生活质量及中医证候量表,旨在量化评估健脾活血颗粒对非酒精性脂肪性肝病的疗效与安全性。

要点

  • 健脾活血颗粒此前在自身对照试验中显示可减少超声图像上的肝脏脂肪变,但缺乏对肝脏脂肪含量的定量观察。
  • 本试验以MRI-PDFF为主要结局,定量评估健脾活血颗粒治疗非酒精性脂肪性肝病的疗效。
  • 计划纳入84例非酒精性脂肪性肝病患者,等比例随机接受健脾活血颗粒或安慰剂治疗24周,干预后12周随访。

核心结论

  • 本试验将采用更受认可且可定量的影像学方法证明健脾活血颗粒治疗非酒精性脂肪性肝病的疗效,并观察其安全性,为其转化应用提供临床证据。

研究设计与样本

  • 随机、双盲、安慰剂对照临床试验,计划纳入84例非酒精性脂肪性肝病参与者,等比例随机接受健脾活血颗粒或安慰剂治疗24周,干预后12周随访。

主要发现

  • 既往研究显示健脾活血颗粒可减少超声图像上的肝脏脂肪变,但缺乏对肝脏脂肪含量的定量观察。
  • 本试验主要结局为基线至第24周MRI-PDFF的变化,次要结局包括体重、体质指数、腰围、腰臀比、血清肝功能、血脂及血糖相关指标、生活质量测量健康调查和中医证候量表。
  • 结局在基线、入组后12周和24周进行监测,试验期间发生的不良事件将及时处理并记录。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Non-alcoholic fatty liver disease (NAFLD) has become the most prevalent form of chronic liver disease, with a global prevalence of 25% worldwide, but a consensus treatment is still lacking. Previous studies have shown that Jian-Pi Huo-Xue granules (JPHX) can reduce hepatic steatosis in ultrasound images, but lacked quantitative observation in imagined liver fat content. This study aimed to refine the efficacy and safety assessment of JPHX for NAFLD with magnetic resonance imaging-proton density fat fraction (MRI-PDFF) as the primary outcome. METHODS: This is a randomized, double-blind, placebo-controlled clinical trial. The trial will enrol 84 NAFLD participants who will be equally randomized to receive either JPHX or a placebo for 24 weeks. Follow-up will be performed 12 weeks after the intervention. The primary outcome will be the change from baseline to week 24 in MRI-PDFF. Secondary outcomes will be the body weight, body mass index (BMI), waist circumference, waist-to-hip ratio (WHR), serum liver function, blood lipids and glucose-related indicators, quality of life measurement health survey, and traditional Chinese medicine (TCM) syndrome scale. Outcomes will be monitored at baseline, 12 weeks and 24 weeks after enrolment. Adverse events occurring in this trial will be managed and recorded promptly. DISCUSSION: We designed a clinical trial for the treatment of NAFLD using JPHX, a TCM formulation that has been shown to have a positive effect on hepatic steatosis in a previous self-controlled trial. This trial will use a more recognized and quantitative imaging approach to demonstrate the efficacy of JPHX in the treatment of NAFLD and observe its safety to provide clinical evidence for its translational applications. TRIAL REGISTRATION: Chinese Clinical Trial Registry ChiCTR2100046132 . Registered on 4 May 2021.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. Sun Y, Chen G, Chen S, et al. Efficacy and safety of Jian-Pi Huo-Xue granule for non-alcoholic fatty liver disease: study protocol for a randomized, double-blind, placebo-controlled trial. Trials. 2022. PMID: 35655225. doi:10.1186/s13063-022-06393-8

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。